The promise of building your own GenAI solution can be tempting. Full control. Custom features. Long-term savings. But in practice, most life sciences organizations find that internal builds are difficult to scale, slow to deliver, and expensive to maintain.

However, technology is only part of the equation when it comes to successful GenAI use. It demands purpose-built workflows, regulatory expertise, continuous updates, and dedicated teams focused entirely on making these tools work in a complex, evolving environment.

If your internal resources are already stretched thin or your AI project is dragging, it might be time to rethink the approach.

We’ve put together a new white paper that lays it all out: “GenAI That Works: How Partnerships Outperform Internal Builds in Pharma.”

It’s a quick but powerful read that breaks down the risks, compares real costs, and shows how to make smarter decisions around AI adoption.

Download the white paper here and get the clarity you need to move forward with confidence.